American College of Gastroenterology Annual Meeting

newsroom

Quizzes

Research Summaries

Conference Coverage

Upadacitinib Superior to Placebo For Moderately to Severely Active Crohn Disease

10/31/2022

A randomized Phase 3 U-ENDURE maintenance study compared the safety and efficacy of upadacitinib with placebo for the treatment of patients with moderate-to-severe Crohn disease.

10/31/2022

Conference Coverage

Risankizumab Significantly Reduces, Resolves Symptoms of Crohn Disease

10/28/2022

The researchers discussed the use of risankizumab induction therapy and its ability to treat symptoms that greatly affect the lives of patients with Crohn disease. The research was presented at ACG 2022. ...

10/28/2022

Conference Coverage

Long-term Subcutaneous Risankizumab is Well-Tolerated in Patients With Moderate-to-Severe Crohn Disease, Delayed Response to IV Risankizumab

10/23/2022

According to a recent study, subcutaneous maintenance dosing of risankizumab at 52 weeks is effective and well-tolerated in patients with moderate-to-severe Crohn disease who had a delayed response to...

10/23/2022

Gastroenterology

Artificial Intelligence May Reduce Radiation Exposure in Fluoroscopy-Guided Endoscopy

10/30/2019

Authors of a new study measured differences in patient radiation exposure and the scatter effect among endoscopy personnel between the use of conventional and artificial intelligence-enabled fluoroscopy...

10/30/2019

gastroenteritis

ENIGMA Study: Novel Antibody Appears Safe, Effective for Eosinophilic GI Disorders

10/29/2019

Because the treatment options for eosinophilic gastrointestinal disorders are limited, authors of the ENIGMA study evaluated whether the AK002 antibody could be a therapy option in eosinophilic gastritis...

10/29/2019

April 2026

Current Issue

April 2026